Pfizer Accupril Patent Invalid Due To Inequitable Conduct, Lawsuit Alleges
Executive Summary
Pfizer hid prior art from Patent & Trademark Office in effort to prolong patent protection for Accupril, a recent lawsuit against the company alleges
You may also be interested in...
Mutual’s Accupril Declaratory Judgment Case Versus Pfizer Thrown Out
Mutual lacks a "reasonable apprehension" of being sued by Pfizer for infringing an Accupril (quinapril) patent, a federal judge ruled March 24
Mutual’s Accupril Declaratory Judgment Case Versus Pfizer Thrown Out
Mutual lacks a "reasonable apprehension" of being sued by Pfizer for infringing an Accupril (quinapril) patent, a federal judge ruled March 24
Accupril patent litigation
Trial in Pfizer's infringement case against Teva relating to the blood pressure agent Accupril (quinapril) will be limited to the validity of Pfizer's formulation patent claims and whether Warner-Lambert engaged in inequitable conduct in obtaining the patent. On Oct. 2, the court granted Pfizer's motion for summary judgment on infringement but rejected the company's motion for summary judgment on the validity of two patent claims...